Modern approaches to treating chronic myelogenous leukemia.
Over the past decade, the treatment of chronic myelogenous leukemia (CML) has gone through significant advances. Once an invariably fatal disease without stem cell transplant, it has since become one of the most manageable hematologic malignancies with good long-term outcomes. However, patients are not cured and require life-long treatment, and unfortunately, some of these patients develop resistant disease that progresses despite our best treatments. As our understanding of CML continues to grow, the repertoire of drugs available for successful treatment also increases. The following review discusses the current and future therapies for CML.
Pinilla-Ibarz
Javier
J
Department of Malignant Hematology, 12902 Magnolia Drive, MRC 3E/3056H, Tampa, FL 33612, USA. javier.pinilla@moffitt.org
Bello
Celeste
C
D001549:Benzamides; D002986:Clinical Trials as Topic; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006801:Humans; D000068877:Imatinib Mesylate; D007167:Immunotherapy / Q000379:methods*; D016898:Interferon-alpha / Q000378:metabolism; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy*; D008495:Medical Oncology / Q000379:methods*; D010879:Piperazines / Q000494:pharmacology / Q000627:therapeutic use; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D016315:Proto-Oncogene Proteins c-abl / Q000378:metabolism; D051562:Proto-Oncogene Proteins c-bcr / Q000378:metabolism; D011743:Pyrimidines / Q000494:pharmacology / Q000627:therapeutic use; D015398:Signal Transduction; D033581:Stem Cell Transplantation / Q000379:methods; D016896:Treatment Outcome
D001549:Benzamides; D004791:Enzyme Inhibitors; D016898:Interferon-alpha; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases; D016315:Proto-Oncogene Proteins c-abl; C496613:BCR protein, human; D051562:Proto-Oncogene Proteins c-bcr